Les inhibiteurs des histones déacétylases : de nouvelles armes thérapeutiques dans le traitement des rhumatismes inflammatoires ?

Fautrel, 2007, Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis, Joint Bone Spine., 74, 627, 10.1016/j.jbspin.2007.10.001 Senolt, 2009, Prospective new biological therapies for rheumatoid arthritis, Autoimmun Rev., 9, 102, 10.1016/j.autrev.2009.03.010 Lioté, 2002, Cytokines et voies de signalisation cellulaire au cours de la polyarthrite rhumatoïde, Rev Rhum, 69, 206 Morel, 2004, Signal transduction pathways: new targets for treating rheumatoid arthritis, Joint Bone Spine, 71, 503, 10.1016/j.jbspin.2004.03.004 Rosato, 2004, Histone deacetylase inhibitors in clinical development, Expert Opin Invest Drugs, 13, 21, 10.1517/13543784.13.1.21 Blanchard, 2005, Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?, Drug Discover Today, 10, 197, 10.1016/S1359-6446(04)03309-4 Glaser, 2007, HDAC inhibitors: clinical update and mechanism based potential, Bioch Pharmacol, 74, 659, 10.1016/j.bcp.2007.04.007 Halili, 2009, Histone deacetylase in inflammatory disease, Curr Top Med Chem, 9, 309, 10.2174/156802609788085250 Grabiec, 2008, Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HAT on?, Arthritis Res Ther, 10, 226, 10.1186/ar2489 Cherrier, 2009, p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1, Oncogene, 28, 3380, 10.1038/onc.2009.193 Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydoxyamic acid SAHA) for refractory cutaneous T cell lymphoma, Blood, 109, 31, 10.1182/blood-2006-06-025999 Yin, 2001, Butyrate suppression of colonocyte NFκB activation and cellular proteasome activity, J Biol Chem, 276, 44641, 10.1074/jbc.M105170200 Segain, 2000, Butyrate inhibits inflammatory response through NFκB inhibition: implications for Crohn's disease, Gut, 47, 397, 10.1136/gut.47.3.397 Ashburner, 2001, The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression, Mol Cell Biol, 21, 7065, 10.1128/MCB.21.20.7065-7077.2001 Imre, 2006, Histone deacetylase inhibitors suppress the inducibility of nuclear factor κ B by tumor necrosis factor α receptor 1 down regulation, Cancer Res, 66, 5409, 10.1158/0008-5472.CAN-05-4225 Viatour, 2003, Cytoplasmic IkappaBalpha increases NF-kappa B-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3, J Biol Chem, 278, 46541, 10.1074/jbc.M306381200 Mahlknecht, 2004, Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression, J Immunol, 173, 3979, 10.4049/jimmunol.173.6.3979 Leoni, 2002, The anti tumor histone deacetylase inhibitor suberoylanilide hydroxyamic acid exhibits anti-inflammatory properties via suppression of cytokines, Proc Natl Acad Sci U S A, 99, 2995, 10.1073/pnas.052702999 Wang, 2009, Using histone deactylase inhibitors to enhance Foxp3+ regulatory T cell function and induce allograft tolerance, Immunol Cell Biol, 87, 195, 10.1038/icb.2008.106 Su, 2008, Epigenetic regulation of established human type 1 versus type 2 cytokine responses, J Allergy Clin Immunol, 121, 57, 10.1016/j.jaci.2007.09.004 Brogdon, 2007, Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function, Blood, 109, 1123, 10.1182/blood-2006-04-019711 Kwon, 2002, Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis, Int J Cancer, 97, 290, 10.1002/ijc.1602 Ito, 2006, Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression, J Exp Med, 203, 7, 10.1084/jem.20050466 Chung, 2003, A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis, Mol Ther, 8, 707, 10.1016/S1525-0016(03)00235-1 Nakamura, 2005, Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production, J Immunol, 175, 5809, 10.4049/jimmunol.175.9.5809 Nishida, 2004, Histone deacetylase inhibitor suppression of autoantibody- mediated arthritis in mice via regulation of p16 INK4a and p21WAFF1/Cip1 expression, Arthritis Rheum, 50, 3365, 10.1002/art.20709 Lin, 2007, Anti rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen induced arthritis in rodents, Br J Pharmacol, 150, 862, 10.1038/sj.bjp.0707165 Nasu, 2008, Trichostatin A, a histone deacetylse inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody induced arthritis mouse model, Osteoarthritis Cart, 16, 723, 10.1016/j.joca.2007.10.014 Saouaf, 2009, Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen induced arthritis, Exp Mol Pathol, 87, 99, 10.1016/j.yexmp.2009.06.003 Huber, 2007, Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid and osteoarthritis patients, Arthritis Rheum, 56, 1087, 10.1002/art.22512 Horiuchi, 2009, Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts, J Rheumatol, 36, 1580, 10.3899/jrheum.081115 Young, 2005, Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption, Arthritis Res Ther, 7, R503, 10.1186/ar1702 Chabane, 2008, Histone deacetylase inhibitors suppress interleukin 1 β-induced nitric oxide and prostaglandin E2 production in human chondrocytes, Osteoarthritis Cart, 16, 1267, 10.1016/j.joca.2008.03.009 Yi, 2007, Trichostatin A mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis, Exp Mol Med, 39, 213, 10.1038/emm.2007.24 Cosio, 2004, Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma, AmJ respi Crit Care Med, 170, 141, 10.1164/rccm.200305-659OC Reynolds, 2006, Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells, Am J Respir Cell Mol Biol., 35, 314, 10.1165/rcmb.2005-0428OC Choo, 2008, Histone deacetylase inhibitors: new hope for rheumatoid arthritis?, Curr Pharm Des, 14, 803, 10.2174/138161208784007699